Atossa Therapeutics Strengthens Leadership to Accelerate Oncology and Rare Disease Treatment Development

Atossa Therapeutics Enhances Clinical Leadership to Advance Targeted Therapies

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical firm renowned for developing innovative treatments for oncology and rare diseases, has strengthened its clinical leadership team with the appointments of Dr. Kathy Puyana Theall as Medical Director - Breast Oncology and Dr. Adebola Giwa as Medical Director - Rare Diseases. This strategic decision aims to bolster the company’s ongoing initiatives in developing (Z)-endoxifen for breast cancer treatment while simultaneously addressing rare conditions such as McCune-Albright syndrome (MAS) and Duchenne Muscular Dystrophy (DMD). These additions reflect Atossa's commitment to accelerating its clinical and regulatory strategies, particularly in the context of high unmet medical needs in these therapeutic areas.

Dr. Theall joins Atossa with over 24 years of experience in breast cancer clinical development, underscoring her capacity to significantly impact drug approval processes. Previously, as Vice President of Clinical Development at Stemline-Menarini, she played an instrumental role in securing FDA approval for ORSERDU™ (elacestrant) in 2023. Additionally, her work at Pfizer involved pivotal contributions to the development of IBRANCE® (palbociclib), a foundational therapy in treating hormone receptor-positive breast cancer. Her extensive background equips her to lead efforts in establishing and executing clinical trial strategies for Atossa’s breast oncology pipeline.

Complementing Dr. Theall's expertise, Dr. Giwa brings a wealth of knowledge in endocrine and rare disease clinical development. His appointment enhances Atossa's capability to advance the therapeutic landscape for rare diseases, which have historically faced challenges in drug development due to their complex nature. Together, Drs. Theall and Giwa's distinguished backgrounds enable Atossa to confidently pursue crucial clinical trials and regulatory milestones, paving the way for potential breakthrough treatments that meet the pressing needs of underserved patient populations.

In light of these appointments, Atossa’s CEO, Dr. Steven Quay, emphasizes the significance of cultivating a top-tier clinical organization. The strategic growth of Atossa's capabilities marks its ongoing commitment to innovation in therapeutic areas that demand urgent attention. The company is on track to transform its clinical pipeline into impactful therapies, emphasizing its position as a leader in both oncology and rare disease treatment development.

The addition of Dr. Theall and Dr. Giwa is a clear indication of Atossa’s focused strategy to not only enhance its clinical development capabilities but to also ensure that it meets rigorous timelines and sets ambitious goals for its research. These appointments serve as a pivotal moment for Atossa, marking a renewed commitment to advancing therapies that will have meaningful impacts on disease management and patient outcomes.